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Abstract
Here we report the case of a disseminated Aspergillus flavus
infection in an adolescent affected by acute lymphoblastic
leukaemia at the beginning of first-line chemotherapy.
Association of surgery and combination antifungal therapy
(high dose liposomal amphotericin B and caspofungin)
allowed infection improvement. 18-FDG PET-MRI was used
for response-to therapy monitoring.
Introduction
Incidence of invasive fungal infections (IFI) has progressively
increased over the past few decades [1]. Invasive aspergillosis
(IA) is associated with the highest morbidity and mortality in
immunocompromised patients [2,3]. Aspergillus flavus is the
second leading cause of IA affecting mostly upper airways and
skin [4,5]. Invasive cutaneous asperigillosis (ICA) is a rare
condition characterized by more or less itching macules,
papules, plaques or haemorrhagic bullae, potentially evolving
into necrotic ulcers covered by a dark eschar. Primary ICA,
deriving from fungus direct inoculation into an injured site, can
be distinguished from secondary ICA, usually resulting from
systemic dissemination of inhaled hyphae through the blood
stream [6-10]. Immunological deficiency in paediatric haemato-
oncology patients is due both to the malignancy and
chemotherapy regimen, emerging as the main predisposing
factors to IFI [11]. Early diagnosis, effective therapy and accurate
response-to-therapy monitoring are mandatory in these
patients, in order to achieve infection control and reintroduce
chemotherapy as soon as possible.
Here we report the case of a proven invasive Aspergillus
flavus infection in an adolescent affected by acute lymphoblastic
leukaemia (ALL), with particular attention to clinical
presentation, therapy schedule and response-to-therapy
monitoring.
Description
A 17 years old girl followed at Paediatric Oncology-
Haematology Clinic of Padova for B-precursor ALL developed a
progressive painful swelling of the left forearm. Diagnosis of B-III
ALL according to EGIL classification [12] was done in August
2016; central nervous system involvement was excluded. Soon
after the diagnosis, the patient was enrolled in AIEOP BFM ALL
2009 international protocol. After the end of the first
chemotherapeutic phase Induction A (prednisone 60
mg/m2/day for 28 days; vincristine 1.5 mg/m2 weekly for 4
doses; daunorubicin 30 mg/m2 weekly for 4 doses; PEG-
asparaginase 2500 UI/m2 for 2 doses every 2 weeks) the patient
developed a painful swelling of the left forearm without
alteration of overlying skin. According to personal history of a
recent accidental trauma and ultrasound findings, the lesion was
initially interpreted as a muscular haematoma. When fever
appeared, the girl was hospitalized and wide spectrum antibiotic
therapy was started (ceftazidime 40 mg/kg/day TID, amikacin 15
mg/kg QD; teicoplanin 10 mg/kg BID the first day, then 10
mg/kg QD), by considering concomitant severe neutropenia and
possible haematoma superinfection. For the persistence of fever
longer than 72 h, according to our local protocol, antibiotic
therapy was shifted to meropenem and antifungal therapy
(liposomial amphotericin B 3 mg/kg QD) was started. During
hospitalization we observed a worsening of the cutaneous
lesions: the first one evolved into a hyperemic painful nodule;
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three analogue new lesions appeared on the left leg and left
arm, one of which covered by a haemorrhagic bullae (Figure 1).
Figure 1: Aspergillus flavus subcutaneous lesions of the left arm
Inflammation indexes were only mildly elevated (maximum C-
reactive protein value: 35 mg/L). Initial Galactomannan (GM)
and 1-3,Beta-D-Glucan (BG) serum dosages were negative.
Ultrasound evaluation and local Magnetic Resonance Imaging
(MRI) showed subcutaneous colliquating abscesses (Figure 2).
Surgical drainage was performed and abundant purulent
material collected: Aspergillus flavus was isolated. According to
previous experience at our Centre in fungal infection diagnosing
and monitoring, a 18-fluorodeoxyglucose Positron Emission
Tomography-MRI (18-FDG PET-MRI)) was performed. This exam
allows to study anatomically and functionally the whole body,
detecting disseminated lesions and minimizing radiation
exposure [13]. Mild to high metabolic uptake (Standardized
Uptake Value–SUV 2.4-4.8) was shown at the following sites:
right leg (2 muscular lesions); left leg (2 subcutaneous lesions);
right dorsal muscles (1 lesion); left arm (2 subcutaneous lesions);
left underarm (1 lymphatic lesion); kidneys (2 parenchymal
lesions); right upper pulmonary lobe (1 lesion). No central
nervous system (CNS) involvement was detected. Eyes
evaluation and echocardiography excluded respectively ocular
and cardiac involvement.
Figure 2 (A): MRI at diagnosis: left arm
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Figure 2 (B): MRI at diagnosis: left limb
Combination antifungal therapy with high dose liposomal
amphotericin B (7.5 mg/kg QD) and caspofungin (70 mg QD the
first day, then 50 mg QD) was started. We opted for this
intensive pharmacological schedule by considering the extension
of fungal infection and the necessity to control it promptly and
reintroduce chemotherapy as soon as possible. Surgical
curettage of subcutaneous abscesses was performed three
times a week by paediatric surgeons. We observed fever
resolution after 3 days of combination therapy and slow
improvement of subcutaneous lesions.
GM was persistently negative, while BG increased
progressively (maximum value>523 pg/ml). After 21 days of
combination therapy we repeated 18-FDG PET-MRI, that showed
a partial improvement of the fungal lesions. This finding allowed
us to start a maintenance chemotherapy with oral methotrexate
and 6-mercaptopurine waiting for a complete resolution of the
infection.
Discussion
Invasive aspergillosis has been emerging as an increasingly
important cause of morbidity and mortality in
immunocompromised children. Aspergillus fumigatus is the
most frequent pathogen, followed by Aspergillus flavus and
Aspergillus terreus [14,15]. IA usually develops soon after
prolonged and severe neutropenia and commonly affects lungs,
less often paranasal sinuses, central nervous system (CNS), skin
and soft tissues. Disseminated form accounts for about 30% of
cases [7,16]. Clinical presentation may be aspecific (i.e.
prolonged fever in severe neutropenia not responding to wide
spectrum antibiotic therapy) or as expression of organ damage
(i.e. cough, pleural pain, and haemoptysis in lung infection or
focal neurological deficits or seizures in CNS localization).
Primary cutaneous aspergillosis has been reported more
frequently in children than in adults, in association with direct
skin lacerations [16,17]. Our patient developed a disseminated
Aspergillus flavus infection with multiple subcutaneous,
muscular and parenchymal lesions. IA is an unexpected finding
in paediatric ALL at the beginning of the first line therapy, as we
observed in our patient: no antifungal prophylaxis is usually
recommended in paediatric ALL [18-20]. Even if patient’s
personal history was positive for a traumatic event,
disseminated IA was more likely the consequence of fungal
vascular migration from an initial pulmonary site than direct
inoculation of Aspergillus flavus into the skin, also considering
that no cutaneous laceration was detected or referred.
IA prognosis mainly depends on early diagnosis, appropriate
treatment and restoration of host defences [21]. Timely
infection control is mandatory in haemato-oncology paediatric
patients, considering that a prolonged interruption of
chemotherapy may affect dramatically the oncological
prognosis. On the other hand IA diagnosis, therapy and
monitoring are still challenging. Isolation of fungal pathogen is
necessary for the definition of proven IA, but is rare and usually
needs surgical approaches [22].
Galactomannan (GM), a polysaccharide cell-wall component
of all Aspergillus spp, is the most accurate marker for IA
screening in adults, but has shown a wide range of true-positive
and true-negative results in paediatric studies (sensitivity 0.76;
specificity 0.86) [23]. In our patient serum GM was repeatedly
negative, even in presence of a proven Aspergillus flavus
infection. 1-3, Beta-D-Glucan (BG) is a cell wall component of
many fungal pathogens such as Aspergillus spp, Candida spp,
Fusarium, Trichosporum or Saccharomyces, and Pneumocystis
jiroveci, whereas lacks in Cryptococcus neoformans and
Mucorales. Its serum testing has been proving to be useful in
adult patients, but data are too limited in children to
recommend [24]. In our patient basal serum BG was negative
and increased progressively during therapy to the maximum
detectable level (>523 pg/ml). In our opinion BG should be
considered as an indicator of the presence or absence of fungal
infection more than an indirect estimator of disease extension.
The increasing serum levels in our patient might be due to
moulds destruction rather than to IA progression.
As regards radiological investigation, CT and MRI have a high
accuracy in the early diagnosis of IA, but may result inadequate
in evaluating disseminated disease and monitoring of residual
infection. Furthermore cumulative radiation exposure due to CT
scan has to be considered, especially in paediatric population
[25,26]. 18-FDG PET-MRI has been recently proposed as a
combined functional-anatomical methodical to better
distinguish active fungal lesions from residual scars [13]. In our
patient 18- FDG PET-MRI allowed to study the whole body,
detected additional lesions and monitored their evolution in
terms of activity and anatomical definition.
No standardized therapy are available, both for the variability
of local epidemiology and paucity of clinical trials [27]. ECIL-5
guidelines recommended monotherapy admistration in IA
(voriconazole 2 x 6 mg/kg the first day, then 2 x 4 mg/kg -
evidence grade AI - or liposomal amphotericin B 3 mg/kg –
evidence grade BI) [18]. Anyway clinical experience seems to
indicate combination therapy as an efficacious treatment of IA in
heamato-oncology paediatric patients, in order to accelerate the
infection control and reduce chemotherapy delay. Association of
caspofungin and voriconazole or caspofungin and liposomal
amphotericin B has been previously described [9,28-30].
Combination therapy with high dose liposomal amphotericin B
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(5-7.5 mg/kg) and caspofungin (70 mg the first day, then 50 mg/
day) was well tolerated in our patient. No renal or liver
impairment was detected. Moderate hypokalemia appeared and
was easily corrected with intravenous potassium chloride
infusion. Surgical curettage of necrotic lesions had a leading role
in the improvement of subcutaneous localizations.
In conclusion, IA is a challenging complication of
chemotherapy-induced immunosuppression in paediatric
haemato-oncology patients. It requires a multidisciplinary
approach in order to obtain promptly the most appropriate
diagnosis. Aggressive therapy is mandatory to control the
infection and allows the clinician to reduce chemotherapy
suspension. 18-FDG PET-MRI may be useful for a more accurate
diagnosis and response-to-therapy monitoring.
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